On July 11, 2025, Raymond James analyst Sean McCutcheon announced the initiation of coverage on Vir Biotechnology (VIR, Financial), assigning an "Outperform" rating to the stock. This move marks the beginning of Raymond James's analytical coverage of VIR, setting the stage for increased investor attention.
The analyst has set a price target of $12.00 USD for Vir Biotechnology (VIR, Financial). This target provides investors with a clear valuation benchmark, although it is important to note that there is no prior price target for comparison as this is the first rating issued by Raymond James for VIR.
The "Outperform" rating suggests that Raymond James anticipates Vir Biotechnology (VIR, Financial) will perform better than the overall market or sector in the near to medium term. Investors may interpret this rating as a positive signal for the stock's potential trajectory.
Stay tuned for more updates and insights on Vir Biotechnology (VIR, Financial) as its market dynamics evolve and further analyst evaluations emerge.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Vir Biotechnology Inc (VIR, Financial) is $18.43 with a high estimate of $31.00 and a low estimate of $12.00. The average target implies an upside of 210.77% from the current price of $5.93. More detailed estimate data can be found on the Vir Biotechnology Inc (VIR) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Vir Biotechnology Inc's (VIR, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Vir Biotechnology Inc (VIR, Financial) in one year is $1.19, suggesting a downside of 79.93% from the current price of $5.93. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Vir Biotechnology Inc (VIR) Summary page.
